{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:58:37Z","timestamp":1794650317674,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1038\/s41391-023-00714-x","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T05:01:40Z","timestamp":1693630900000},"page":"312-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Histopathological concordance between prostate biopsies and radical prostatectomy specimens\u2014implications of transrectal and transperineal biopsy approaches"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-0201","authenticated-orcid":false,"given":"M. J.","family":"Hagens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. L. A.","family":"Ribbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2297-8179","authenticated-orcid":false,"given":"H.","family":"Veerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Barwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Boodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. E.","family":"de Bruijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Claessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Leter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-4535","authenticated-orcid":false,"given":"V.","family":"van der Noort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Smeenge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. A.","family":"Roeleveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"Rynja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Weltings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3419-3368","authenticated-orcid":false,"given":"A. N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. G.","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,2]]},"reference":[{"key":"714_CR1","doi-asserted-by":"crossref","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243\u201362.","DOI":"10.1016\/j.eururo.2020.09.042"},{"key":"714_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. Grading committee. The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244\u201352.","journal-title":"Am J Surg Pathol"},{"key":"714_CR3","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"GJLH van Leenders","year":"2020","unstructured":"van Leenders GJLH, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, et al. ISUP grading workshop panel members. The 2019 international society of urological pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol. 2020;44:e87\u201399.","journal-title":"Am J Surg Pathol"},{"key":"714_CR4","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.euf.2021.04.011","volume":"8","author":"M Wenzel","year":"2022","unstructured":"Wenzel M, W\u00fcrnschimmel C, Chierigo F, Mori K, Tian Z, Terrone C, et al. Pattern of Biopsy Gleason grade group 5 (4 + 5 vs 5 + 4 vs 5 + 5) predicts survival after radical prostatectomy or external beam radiation therapy. Eur Urol Focus. 2022;8:710\u20137.","journal-title":"Eur Urol Focus"},{"key":"714_CR5","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.euf.2021.07.008","volume":"8","author":"M Wenzel","year":"2022","unstructured":"Wenzel M, W\u00fcrnschimmel C, Chierigo F, Flammia RS, Tian Z, Shariat SF, et al. Nomogram predicting downgrading in national comprehensive cancer network high-risk prostate cancer patients treated with radical prostatectomy. Eur Urol Focus. 2022;8:1133\u201340.","journal-title":"Eur Urol Focus"},{"key":"714_CR6","doi-asserted-by":"publisher","first-page":"E202","DOI":"10.1111\/j.1464-410X.2011.10119.x","volume":"108","author":"NM Corcoran","year":"2011","unstructured":"Corcoran NM, Hong MK, Casey RG, Hurtado-Coll A, Peters J, Harewood L, et al. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int. 2011;108:E202\u201310.","journal-title":"BJU Int"},{"key":"714_CR7","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1002\/cncr.24283","volume":"115","author":"LG Taylor","year":"2009","unstructured":"Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115:2388\u201399.","journal-title":"Cancer."},{"key":"714_CR8","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00345-019-02634-9","volume":"37","author":"R Diamand","year":"2019","unstructured":"Diamand R, Oderda M, Al Hajj Obeid W, Albisinni S, Van Velthoven R, Fasolis G, et al. A multicentric study on accurate grading of prostate cancer with systematic and MRI\/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy. World J Urol. 2019;37:2109\u201317.","journal-title":"World J Urol"},{"key":"714_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N. Engl J Med. 2020;382:917\u201328.","journal-title":"N. Engl J Med"},{"key":"714_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.euo.2019.08.001","volume":"3","author":"S Goel","year":"2020","unstructured":"Goel S, Shoag JE, Gross MD, Al Hussein Al Awamlh B, Robinson B, Khani F, et al. Concordance between biopsy and radical prostatectomy pathology in the era of targeted biopsy: a systematic review and meta-analysis. Eur Urol Oncol. 2020;3:10\u201320.","journal-title":"Eur Urol Oncol"},{"key":"714_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1445-2197.2005.03284.x","volume":"75","author":"J Miller","year":"2005","unstructured":"Miller J, Perumalla C, Heap G. Complications of transrectal versus transperineal prostate biopsy. ANZ J Surg. 2005;75:48\u201350.","journal-title":"ANZ J Surg"},{"key":"714_CR12","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.eururo.2011.12.058","volume":"61","author":"S Loeb","year":"2012","unstructured":"Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schr\u00f6der FH, Roobol MJ. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol. 2012;61:1110\u20134.","journal-title":"Eur Urol"},{"key":"714_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/bju.12536","volume":"114","author":"JP Grummet","year":"2014","unstructured":"Grummet JP, Weerakoon M, Huang S, Lawrentschuk N, Frydenberg M, Moon DA, et al. Sepsis and \u201csuperbugs\u201d: should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int. 2014;114:384\u20138.","journal-title":"BJU Int"},{"key":"714_CR14","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1097\/JU.0000000000002802","volume":"208","author":"F Zattoni","year":"2022","unstructured":"Zattoni F, Marra G, Kasivisvanathan V, Grummet J, Nandurkar R, Ploussard G, et al. The detection of prostate cancer with magnetic resonance imaging-targeted prostate biopsies is superior with the transperineal vs the transrectal approach. a European association of urology-young academic urologists prostate cancer working group multi-institutional study. J Urol. 2022;208:830\u20137.","journal-title":"J Urol"},{"key":"714_CR15","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.euo.2020.12.012","volume":"4","author":"BP Rai","year":"2021","unstructured":"Rai BP, Mayerhofer C, Somani BK, Kallidonis P, Nagele U, Tokas T. Magnetic resonance imaging\/ultrasound fusion-guided transperineal versus magnetic resonance imaging\/ultrasound fusion-guided transrectal prostate biopsy-a systematic review. Eur Urol Oncol. 2021;4:904\u201313.","journal-title":"Eur Urol Oncol"},{"key":"714_CR16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019;76:340\u201351.","journal-title":"Eur Urol"},{"key":"714_CR17","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1007\/s00330-020-06929-z","volume":"30","author":"M de Rooij","year":"2020","unstructured":"de Rooij M, Isra\u00ebl B, Tummers M, Ahmed HU, Barrett T, Giganti F, et al. ESUR\/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists\u2019 training. Eur Radio. 2020;30:5404\u201316.","journal-title":"Eur Radio"},{"key":"714_CR18","doi-asserted-by":"crossref","unstructured":"Wegelin O, Exterkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC, et al. The FUTURE trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies. Eur Urol. 2019;75:582\u201390.","DOI":"10.1016\/j.eururo.2018.11.040"},{"key":"714_CR19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","volume":"199","author":"MG Sanda","year":"2018","unstructured":"Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline. part I: risk stratification, shared decision making, and care options. J Urol. 2018;199:683\u201390.","journal-title":"J Urol"},{"key":"714_CR20","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.eururo.2012.01.050","volume":"61","author":"JI Epstein","year":"2012","unstructured":"Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 2012;61:1019\u201324.","journal-title":"Eur Urol"},{"key":"714_CR21","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s11255-021-03007-1","volume":"53","author":"LG Qu","year":"2021","unstructured":"Qu LG, Al-Shawi M, Howard T, Papa N, Poyet C, Kelly B, et al. Gleason grade accuracy of transperineal and transrectal prostate biopsies in MRI-na\u00efve patients. Int Urol Nephrol. 2021;53:2445\u201352.","journal-title":"Int Urol Nephrol"},{"key":"714_CR22","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000471491","volume":"99","author":"G Marra","year":"2017","unstructured":"Marra G, Eldred-Evans D, Challacombe B, Van Hemelrijck M, Polson A, Pomplun S, et al. Pathological concordance between prostate biopsies and radical prostatectomy using transperineal sector mapping biopsies: validation and comparison with transrectal biopsies. Urol Int. 2017;99:168\u201376.","journal-title":"Urol Int"},{"key":"714_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.prnil.2016.07.004","volume":"4","author":"SM Evans","year":"2016","unstructured":"Evans SM, Patabendi Bandarage V, Kronborg C, Earnest A, Millar J, Clouston D. Gleason group concordance between biopsy and radical prostatectomy specimens: a cohort study from prostate cancer outcome registry - Victoria. Prostate Int. 2016;4:145\u201351.","journal-title":"Prostate Int"},{"key":"714_CR24","doi-asserted-by":"crossref","unstructured":"Zattoni F, Marra G, Martini A, Kasivisvanathan V, Grummet J, Harkin T, et al. Is there an impact of transperineal vs. transrectal mri-targeted biopsy on the risk of upgrading in final pathology in prostate cancer patients undergoing radical prostatectomy? An EAU-YAU prostate cancer working group multi-institutional study. Eur Urol Focus. 2023;9:621\u20138.","DOI":"10.1016\/S0302-2838(23)00343-3"},{"key":"714_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5124-9","volume":"18","author":"Z Mai","year":"2018","unstructured":"Mai Z, Zhou Z, Yan W, Xiao Y, Zhou Y, Liang Z, et al. The transverse and vertical distribution of prostate cancer in biopsy and radical prostatectomy specimens. BMC Cancer. 2018;18:1205.","journal-title":"BMC Cancer"},{"key":"714_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/bju.15124","volume":"126","author":"T Cowan","year":"2020","unstructured":"Cowan T, Baker E, McCray G, Reeves F, Houlihan K, Johns-Putra L. Detection of clinically significant cancer in the anterior prostate by transperineal biopsy. BJU Int. 2020;126:33\u20137.","journal-title":"BJU Int"},{"key":"714_CR27","doi-asserted-by":"crossref","unstructured":"Hagens MJ, Luining WI, Jager A, Donswijk ML, Cheung Z, Wondergem M, et al. The diagnostic value of PSMA PET\/CT in men with newly diagnosed unfavorable intermediate-risk prostate cancer. J Nucl Med. 2023;64:1238\u201343.","DOI":"10.2967\/jnumed.122.265205"},{"key":"714_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.prnil.2022.01.004","volume":"10","author":"B Hoeh","year":"2022","unstructured":"Hoeh B, Flammia R, Hohenhorst L, Sorce G, Chierigo F, Tian Z, et al. Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer. Prostate Int. 2022;10:21\u20137.","journal-title":"Prostate Int"},{"key":"714_CR29","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/JU.0000000000001074","volume":"204","author":"W Ranasinghe","year":"2020","unstructured":"Ranasinghe W, Reichard CA, Nyame YA, Sundi D, Tosoian JJ, Wilkins L, et al. Downgrading from Biopsy grade group 4 prostate cancer in patients undergoing radical prostatectomy for high or very high risk prostate cancer. J Urol. 2020;204:748\u201353.","journal-title":"J Urol"},{"key":"714_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-019-0526-9","volume":"19","author":"N Bullock","year":"2019","unstructured":"Bullock N, Simpkin A, Fowler S, Varma M, Kynaston H, Narahari K. Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British Association of Urological Surgeons Radical Prostatectomy Registry. BMC Urol. 2019;19:94.","journal-title":"BMC Urol"},{"key":"714_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1470-2045(19)30739-9","volume":"21","author":"W Bulten","year":"2020","unstructured":"Bulten W, Pinckaers H, van Boven H, Vink R, de Bel T, van Ginneken B, et al. Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study. Lancet Oncol. 2020;21:233\u201341.","journal-title":"Lancet Oncol"},{"key":"714_CR32","doi-asserted-by":"crossref","unstructured":"De Luca S, Fiori C, Bollito E, Garrou D, Aimar R, Cattaneo G, et al. Risk of Gleason Score 3\u2009+\u20094\u2009=\u20097 prostate cancer upgrading at radical prostatectomy is significantly reduced by targeted versus standard biopsy. Minerva Urol Nefrol. 2020;72:360\u20138.","DOI":"10.23736\/S0393-2249.19.03367-8"},{"key":"714_CR33","doi-asserted-by":"crossref","unstructured":"Mandel P, Wenzel M, Hoeh B, Welte MN, Preisser F, Inam T, et al. Immunohistochemistry for prostate Biopsy-impact on histological prostate cancer diagnoses and clinical decision making. Curr Oncol. 2021;28:2123\u201333.","DOI":"10.3390\/curroncol28030197"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-023-00714-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-023-00714-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-023-00714-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T11:04:08Z","timestamp":1715771048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-023-00714-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["714"],"URL":"https:\/\/doi.org\/10.1038\/s41391-023-00714-x","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,2]]},"assertion":[{"value":"31 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}